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Resuscitative retrograde blood cardioplegia 
Are amino acids or continuous warm techniques necessary? 
This experiment was designed to determine the relative degree of cardiac functional recovery 
provided by various forms of resuscitative retrograde blood cardioplegia fter global ischemic injury. 
Twenty-four dogs were subjected to 20 minutes of normothermic global myocardial ischemia followed 
by 60 minutes of cardioplegic arrest by one of three methods: group 1, standard cold blood 
cardioplegia with a cold terminal dose (n = 8); group 2, aspartate-glutamate-enhanced blood 
cardioplegia with warm induction and terminal enhancement (n = 8); and group 3, continuous warm 
blood cardioplegia (n = 8). Sonomicrometry was used to analyze left ventricular function for 
maximal elastance and preload recruitable stroke work area. Data were recorded at baseline and 
after 30 and 60 minutes of unloaded reperfusion. The results showed improved early recovery of 
preload recruitable stroke work area, but not of maximal elastance, after reperfusion of ischemic 
hearts with warm resuscitative blood cardioplegic solution enhanced with amino acids. The 
functional improvement provided by this technique was transient, however, and no significant 
differences were detectable among the groups after 60 minutes of unloaded reperfusion. Neither 
amino acid enhancement nor continuous warm cardioplegia offered a significant advantage in 
functional recovery over the standard method of cold blood cardioplegia reperfusion. (J THORAC 
CARDIOVASC SURG 1995;109:242-8) 
Tohru Asai, MD, Eugene A. Grossi, MD, Martin LeBoutillier III, MD, 
Michael A. Parish, MD, F. Gregory Baumann, PhD, Frank C. Spencer, MD, 
Stephen B. Colvin, MD, and Aubrey C. Galloway, MD, New York, N.Y. 
R,  ecent experimental data from our laboratory 
have shown that infusion of warm cardioplegic 
solution enhanced with amino acids provides no 
additional benefit for routine myocardial protection, 
even with prolonged aortic crossclamp times) Prior 
studies have also demonstrated nearly total myocar- 
dial functional recovery after aortic crossclamp 
times of 2 to 4 hours when multidose cold blood 
potassium cardioplegic solution was used. 2Myocar- 
dial protection for most patients, therefore, should 
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focus on providing ood distribution of cardioplegic 
solution with uniform myocardial cooling. 
In contrast, several reports based on ischemic 
injury models have noted improved recovery of 
cardiac function after the use of warm cardioplegic 
solution enhanced with amino acids. 3-8 The investi- 
gators theorized that the addition of amino acids to 
the reperfusate of ischemic myocardium provides 
supplemental substrates to hasten recovery of myo- 
cardial high-energy phosphates and that the warm 
temperature contributes to optimal myocardial en- 
zyme function, oxygen extraction, and repayment 
of oxygen debt. 3-5' 9 In addition, some investiga- 
tors have recently suggested that warm continuous 
cardioplegia may be beneficial to the damaged 
heart, 1°-13 and this technique has been recom- 
mended for high-risk patients with ongoing ischemia 
or cardiogenic shock. In view of these recent recom- 
mendations, this experiment was designed to assess 
relative myocardial functional recovery after isch- 
emic injury when these different clinical methods of 
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Table I. Components of blood cardioplegic solution by group (final concentration on delivery to animal) 
Group 1: Group 2: Group 3: 
Standard cold Amino acids Fremes' olution 
5% Dextrose in 0.2% saline 500 ml 
5% Dextrose in water 200 ml 500 ml 
Potassium 
High (20-24 mEq/L) 100 mEq 100 mEq 50 mEq 
Low (8-12 mEq/L) 40 mEq 40 mEq 30 mEq 
Magnesium sulfate (3-4 mEq/L) 9 mEq 
THAM (pH 7.6) 200 ml 20 ml 
CPD (0.4-0.6 mmol/L Ca ++) 200 ml 10 ml 
50% Dextrose 45 ml 
Aspartate 
Glutamate 
Amino acid solution in water 
Osmolarity >400 mOsm >400 mOsm 
200 ml 
200 ml 
45 ml 
9.81 gm (13 mmol/L) 
10.69 gm (13 retool/L) 
250 ml 
>400 mOsm 
THAM, Tromethamine; CPD, citrate-phosphate-dextrose. 
retrograde resuscitative cardioplegia are used as 
adjuncts to left ventr icular (LV) unloading during 
reperfusion. 
Materials and methods 
Preparation. Twenty-four heartworm-free adult mon- 
grel dogs (25 to 30 kg) were anesthetized with metocurine 
iodide (Metubine, 0.5 mg/kg) and c~-chloralose (100 mg/ 
kg), intubated, and supported with a mechanical ventilator 
(Harvard Apparatus Co., Dover, Mass.). All animals 
received humane care in compliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Institute 
of Laboratory Animal Resources and published by the 
National Institutes of Health (NIH publication No. 86-23, 
revised 1985). The femoral artery and vein were instru- 
mented for pressure tracings; arterial blood gases and 
serum electrolytes were monitored and kept within phys- 
iologic range during the entire procedure. 
Experimental protocol. A median sternotomy was per- 
formed, the azygos vein ligated, and the pericardium 
fashioned into a cradle. The major and minor ventricular 
axes and wall thickness of the LV were instrumented with 
two pairs of piezoelectric crystals (Triton Technology, San 
Diego, Calif.), as previously described. 1 A transmural 
needle biopsy was taken from the LV for ultrastructure 
evaluation, and an LV pressure catheter (Millar Instru- 
ments, Inc., Houston, Tex.), as well as a ventricular vent, 
was placed via the LV apex. The sinus node was excised 
and the right atrium was paced at a rate of 150 beats/min. 
Total cardiopulmonary bypass was established via the 
femoral artery with bicaval cannulation. Another arterial 
cannula was inserted into the main pulmonary artery for 
right heart bypass. For data collection the preparation was 
switched from total heart-lung bypass with the LV vented 
to a right heart bypass model with a fully working LV. 
All animals were subjected to 20 minutes of normother- 
mic global myocardial ischemia by crossclamping the 
aorta. The aortic root and ventricular chambers were 
vented during this time; all hearts fibrillated within several 
minutes. Concurrently, the right atrium was opened lat- 
erally through a vertical incision and a pursestring suture 
was placed around the coronary sinus. Immediately before 
the end of the 20 minutes of ischemia a coronary sinus 
cardioplegia catheter (Shiley, Inc., Irvine, Calif.) was 
placed in the coronary sinus and the pursestring suture 
was snared. Blood cardioplegic solution was injected by 
means of one of the three reperfusion methods described 
herein. After 60 minutes of protected arrest, the aorta was 
unclamped, the retrograde coronary sinus catheter was 
removed, and the hearts were defibrillated. Whole blood 
reperfusion proceeded for an additional hour, with the 
ventricles fully unloaded and not ejecting. 
Functional data were obtained before ischemia nd at 
30 minutes and 60 minutes after unclamping. Blood 
volume was added to the left side of the heart to raise the 
LV end-diastolic pressure to approximately 22 mm Hg 
and then withdrawn to create a series of pressure-volume 
loops. When the experiment had been completed, trans- 
mural myocardial specimens were obtained for water 
content and ultrastructure analysis. 
Experimental groups. Animals were randomly placed 
into one of three cardioplegia groups, with eight animals 
per group: group 1, standard multidose cold blood cardio- 
plegia with a cold terminal dose; group 2, aspartate- 
glutamate-enhanced multidose cold blood cardioplegia, 
with warm induction and warm terminal enhancement 
injections; and group 3, continuous warm cardioplegia 
with Fremes' solution. 12 The cardioplegic solutions in 
groups 1 and 2 were identical except for the presence of 
amino acid enhancement in group 2, whereas the compo- 
sition of group 3 solution was slightly different (Table I). 
All groups received cardioplegic solution in retrograde 
fashion with flow rates of 100 ml/min. 
For groups 1 and 2 oxygenated blood was cooled to 4 ° C 
in a BCD Plus heat exchanger (Shiley) and mixed 4:1 with 
cardioplegic solution. In group 2 the cardioplegic solution 
was enhanced with both aspartate and glutamate in a 
concentration of 13 mmol/L. Groups 1 and 2 received an 
initial dose of high-potassium cardioplegic solution (20 
ml/kg of 20 to 24 mEq/L), with subsequent doses of 
low-potassium cardioplegic solution (10 ml/kg of 8 to 12 
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Table II. PRSW results by treatment group 
Treatment groups 
Group 1 Group 2 Group 3 
Preclamp slope (erg ×103/ml) 153.1 + 15.9 126.6 _+ 9.77 153.3 _+ 9.31 
30 min slope (erg ×103/ml) 68.3 _+ 11.7 88.7 _+ 10.4" 74.8 _+ 90.6 
(46.3%) (69.7%) (49.4%) 
60 rain slope (erg ×103/ml) 76.6 -+ 17.9 77.5 -+ 11.6 85.8 + 18.0 
(48.9%) (60.4%) (56.4%) 
Preclamp intercept (ml) 16.6 _+ 2.8 22.0 _+ 3.5 14.2 _+ 2.4 
30 rain intercept (ml) 27.4 _+ 4.25 30.5 _+ 4.15 23.9 +_ 4.69 
(171.2%) (149.2%) (165.2%) 
60 min intercept (ml) 26.4 + 4.20 31.5 _+ 4.42 23.1 _+ 4.65 
(164.5%) (153.1%) (156.8%) 
Preclamp PRWA 54,299 _+ 12,839 73,411 _+ 24,787 76,325 _+ 20,742 
30 min PRWA 7,321 _+ 1,061 26,930 _+ 8,036* 15,498 +_ 3,129 
(17.7%) (43.4%) (28.1%) 
60 rain PRWA 8,797 + 1,312 23,112 _+ 9,900 16,802 +_ 2,983 
(25.7%) (37.1%) (38.3%) 
Values are absolute mean -- standard error of the mean (percent change of mean from pre-crossclamping control value). 
*p < 0.05 by repeated-measures analysis ofvariance. 
mEq/L) every 15 minutes. In group 1 all doses were given 
at 6 ° C. For group 2 the first dose was initially given at 
36 ° C (10 ml/kg) and then switched to 6 ° C (10 ml/kg), as 
were subsequent doses; the terminal dose was given at 
36 ° C. In group 3 cardioplegic solution was given contin- 
uously at 36 ° C to maintain a coronary sinus pressure of 35 
to 45 mm Hg. Initially, high-potassium (20 to 24 mEq/L) 
cardioplegic solution was used to arrest the heart, after 
which the solution was changed to a low potassium 
concentration (8 to 12 mEq/L). In groups I and II the 
systemic perfusate was kept at 30°C until 15 minutes 
before unclamping, when it was warmed to 36 ° C. In group 
3 it was kept at 36 ° C. In all groups the hematocrit value 
during bypass was between 20% and 26%. 
Ultrastructural examination. Ultrastructural examina- 
tion was performed on transmural needle biopsy speci- 
mens of LV tissue obtained from each animal at baseline 
and after 60 minutes of reperfusion. These specimens 
were rapidly immersed in fresh, cold, 3% glutaraldehyde 
in Sorensen's phosphate buffer (0.1 mol/L, pH 7.3) for 24 
hours. The specimens were postfixed in 1% osmium 
tetroxide, dehydrated in acetone, and embedded in Epon 
fixative. "Green" specimens, 0.5 to 1 /xm thick, were cut, 
stained with a polychrome stain, and examined by light 
microscopy. Corresponding thin sections were cut on an 
LKB Ultratome III ultramicrotome (LKB Instruments, 
Inc., Rockville, Md.), mounted on coated copper grids, 
stained with uranyl acetate and lead citrate, and examined 
with a Siemens transmission electron microscope (Si- 
emens Corp., Union, N.J.). 
Collection and analysis of myocardial function data. 
Data were collected during each of the measurement 
periods (before ischemia nd at 30 and 60 minutes after 
unclamping). Three sets of bicaval occlusions were per- 
formed at each experimental point, as described previous- 
ly. 1 During this period data were collected for 30 seconds 
on-line with eaval occlusion occurring after 5 steady-state 
cycles and zero stroke work being achieved within 30 sec- 
onds. All data were filtered by a 50 Hz low-pass analog filter 
and digitized in real time by an analog/digital converter with 
a sampling rate of 200 Hz. The effective sampling interval 
was 4 msec throughout the cardiac ycle. The data were then 
recorded on-line by an IBM computer (IBM Corp., Armonk, 
N.Y.). Laboratory videographic verification of the pressure 
dimension data was performed before storage. 
Data were subsequently analyzed with computer soft- 
ware developed in our laboratory. The method for mea- 
suring cardiac function was based on algorithms devel- 
oped by other investigators using a prolated ellipse 
modela4, 15 and is briefly described as follows. Cardiac 
cycles were defined as the rate of first positive pressure 
rise (dP/dt) crossing threshold 500 mm Hg/sec after 
maximum negative dP/dt. The end-diastolic time was 
marked as -40 msec before maximum dP/dt. Visual 
plotting of dP/dt versus time and pressure-volume loops 
with end-diastolic time marked confirmed the accuracy of 
these definitions for each data acquisition interval. The 
stroke work was determined as the area within the pres- 
sure-volume loop by numeric integration, the preload 
recruitable work area (PRWA). Likewise the LV volume 
was determined by the formula: 
1r 
V= 
6(a - 2h) (b - 2h) 2 
where V = LV internal volume, a = LV major axis 
diameter, b = LV external minor-axis diameter, and h = 
LV equatorial wall thickness. 
Manual review of all cycles in each occlusion was 
performed to eliminate those with gross tracking errors or 
electronic artifact. All cardiac ycles with maximum dP/dt 
below 500 mm Hg/sec or stroke work area less than 10% 
of the resting steady state were discarded. The stroke 
work was then automatically regressed against he end- 
diastolic volume to obtain the slope (M) and x-intercept 
(Vo, LV end-diastolic volume at zero stroke work) of the 
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Table I lL Elastance results by treatment group 
Treatment groups 
Group 1 Group 2 Group 3 
Preclamp slope (erg × 103/ml) 
30 min slope (erg x103/ml) 
60 min slope (erg ×103/ml) 
Preclamp intercept (ml) 
30 rain intercept (ml) 
60 rain intercept (ml) 
20.9 + 5.72 21.7 -2-_ 2.30 27.7 + 6.16 
9.46 -+ 3.20 10.05 -+ 1.81 16.28 + 5.90 
(44.7%) (47.4%) (53.6%) 
9.41 -+ 2.71 9.98 -+ 2.10 24.0 -+ 11.92 
(45.8%) (52.0%) (70.0%) 
12.9 _+ 2.73 12.8 _+ 2.45 8.25 _+ 2.16 
16.8 _+ 6.12 20.8 _+ 4.02 16.3 - 4.21 
(165.1%) (169.6%) (226.1%) 
23.1 _+ 3.45 20.4 -+ 3.82 15.5 _+ 3.92 
(170.2%) (167.8%) (199.6%) 
Values are absolute mean -+ standard error of the mean (percent change 
linear preload- and afterload-independent cardiac function 
curve, termed preload recruitable stroke work (PRSW). 16 The 
systolic function was analyzed by computing maximal elas- 
tance. 17 Regression of both PRSW and maximal elastance 
generated linear relationships with high coefficients greater 
than 0.90. 
Data were analyzed by repeated-measures analysis of 
variance performed on absolute numbers with SPSS soft- 
ware (SPSS, Chicago, Ill.), and significance was accepted 
when the p value was less than 0.05. Analysis of variance 
revealed that the experimental design was capable of 
detecting differences of 12% or less (power of test = 0.80; 
p = 0.05; two-tailed test). 
Results 
Analysis of diastolic function revealed significant 
improvement of end-diastolic function with amino 
acid-enhanced cardioplegic solution at 30 minutes 
as compared with both standard cold and continu- 
ous warm cardioplegia (Table II). The amino acid 
cardioplegia group recovered 69.7% of its baseline 
PRSW slope after 30 minutes of reperfusion, whereas 
the standard cold cardioplegia nd warm continuous 
cardioplegia groups recovered 46.3% and 49.4% of 
baseline slope, respectively (p < 0.05 for group 2 
versus groups 1 and 3). This significant difference, 
however, was not sustained to 60 minutes of reperfu- 
sion, at which time the percent of baseline PRWA 
slope was 48.9%, 60.4%, and 56.4% for groups 1, 2, 
and 3, respectively (Table II). Similar results were 
noted from analysis of PRWA: amino acid cardiople- 
gia provided significantly better function at 30 minutes 
with 43.4% recovery of baseline function as compared 
with 17.7% for standard cold and 28.1% for warm 
continuous cardioplegia. After 60 minutes of unloaded 
reperfusion, however, no statistically significant differ- 
ence in recovery of PRWA was measurable among the 
three groups, with PRWAs of 25.7%, 37.1%, and 
38.3%, respectively (Table II). 
of mean from pre-crossclamping control value). 
Table IV. Water content of myocardial biopsy tissue 
after 60 minutes of reperfusion 
Group 1 Group 2 Group 3
Wet weight (mg) 1547 _+ 263 1424 _+ 136 1138 +_ 108 
Dry weight (mg) 408 _ 56.2 414 -2_ 55.0 3376 -+ 66.8 
Percent water content 81.0 - 0.3 79.0 +_ 0.5* 79.8 _+ 0.5 
Values are absolute or percent mean --_ standard error of the mean. 
*p < 0.05 by Tukey's multiple range test. 
Analysis of elastance data demonstrated slightly 
better function in the warm continuous cardioplegia 
group, but this difference did not prove statistically 
significant. Recovery of elastanee at 30 and 60 
minutes was 44.7% and 45.8% for cold cardioplegia, 
47.4% and 52.0% for amino acid-enhanced cardio- 
plegia, and 53.6% and 70.0% for warm continuous 
cardioplegia (Table III). 
Microscopic and ultrastntctural examination of 
the changes from baseline in the biopsy specimens 
taken from each animal after 60 minutes of reper- 
fusion showed no qualitative differences among 
groups. All tissue looked relatively normal, and each 
group showed only the expected egree of myocyte 
necrosis, mitoehondrial nd myofilament abnormal- 
ities, cell membrane disruption, and microvascular 
blockage or wall disruption. 
Water content analysis revealed significantly less 
edema in the amino acid cardioplegia group 
(79.0%) than in the cold cardioplegia group (81.0%) 
at 1 hour after reperfusion (Table IV). 
Discussion 
In this study the addition of aspartate and gluta- 
mate to resuscitative cardioplegia resulted in a 
positive but transient effect on LV functional recov- 
ery after ischemic injury. The form of ischemic 
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injury caused by the experimental methods used 
here might be characterized as "myocardial stun- 
ning" in that a relatively brief period of global 
ischemia (20 minutes) was followed by a period of 
contractile dysfunction, presumably transient, on 
reperfusion. TM A principal factor in such "stunning" 
has been reported to be the generation of oxygen- 
derived free radicals on initial reperfusion. 19
Previous work by other groups has indicated that 
amino acid substrate nhancement and warm car- 
dioplegia reperfusion improve both metabolic re- 
covery and short-term functional recovery after both 
regional and global myocardial ischemic injury. 3-9 It 
should be noted that numerous differences in design 
and methods exist between this study and the prin- 
cipal previous experimental study suggesting benefit 
from amino acid supplementation f resuscitative 
cardioplegia. 7 In particular, the earlier study (1) 
combined 45 minutes of ischemic injury with brief 
reperfusion as the form of myocardial injury, (2) 
used antegrade cardioplegia instead of the retro- 
grade cardioplegia used here (the retrograde cardio- 
plegia also had a flow rate high enough possibly to 
cause some shunting of cardioplegic solution away 
from the capillary nutritive system), (3) measured 
the intermittent doses of cardioplegic solution in 
terms of duration of administration rather than on 
a body weight basis, and (4) gauged recovery of 
myocardial function after reperfusion more indi- 
rectly by measuring changes in myocardial oxygen 
uptake and stroke-work index instead of changes in 
PRWA and maximal elastance. 
Despite these differences, however, the earlier 
investigators noted an improvement in myocardial 
recovery after 30 minutes of reperfusion in the 
group receiving amino acid supplementation, as we 
did. Unfortunately, they did not go on to measure 
the durability of this improvement beyond 30 min- 
utes of reperfusion. 7 In the present study this early 
improvement in myocardial function noted in the 
amino acid cardioplegia group had disappeared by 
the end of 1 hour of unloaded reperfusion. Clearly 
the results do not demonstrate sustained improve- 
ment in LV functional recovery after use of the 
warm amino acid reperfusion method. This obser- 
vation is consistent with prior results on regional 
infarction from our laboratory, which demonstrated 
no significant additional reduction in final infarct 
size with amino acid cardioplegia compared with 
cold blood cardioplegia when these techniques were 
used as adjuncts to mechanical cardiac unloading. 2° 
Furthermore, a terminal cold "washout" dose of 
standard low-calcium blood cardioplegia may have 
been equally effective in minimizing oxygen-derived 
free radical and calcium-induced reperfusion i jury. 
Dennis and associates 21have previously demon- 
strated that total unloading of the LV reduced 
myocardial oxygen consumption by 50%, and later 
application of this technique for an evolving infarc- 
tion provided substantial reduction in final infarct 
size.20, 22, 23 The addition of a cardioplegia regimen 
before controlled, unloaded reperfusion has been 
shown to have a small, incremental effect on limita- 
tion of final infarct size. 6' 20, 24-29 Although the ad- 
dition of amino acids for substrate enhancement and 
the use of warm blood cardioplegia to optimize 
enzyme function and oxygen extraction are appeal- 
ing on a theoretic basis, this approach as not been 
convincingly shown to significantly reduce infarct 
size beyond that obtained with unloaded reperfu- 
sion in combination with standard cold blood car- 
dioplegia. On the basis of the data in the current 
study, the warm blood amino acid-enhanced reper- 
fusion method seemed to improve short-term car- 
diac functional recovery, but the effect was transient. 
Perhaps the functional improvement seen with the 
warm amino acid-enhanced resuscitative method 
would have been more sustained had the duration of 
controlled reperfusion been longer, as proposed by 
Allen and colleagues. 6 This would theoretically al- 
low better repayment of the oxygen debt, with 
improved function of cells that have had borderline 
injury. 
Nevertheless, the findings of this report are par- 
ticularly pertinent because both amino acid-en- 
hanced resuscitative cardioplegia nd warm contin- 
uous cardioplegia techniques have been proposed 
recently as better clinical alternatives for surgical 
protection of acutely ischemic myocardium. The 
results reported here suggest hat standard low- 
calcium cold blood cardioplegia, used with a final 
"washout" dose before unclamping and in combina- 
tion with vented reperfusion, may be equally effec- 
tual in minimizing reperfusion i jury. Further study 
is necessary, inasmuch as more complex or costly 
methods for reperfusing ischemic myocardium dur- 
ing operations cannot be justified unless sustained 
functional benefits can be clearly demonstrated. 
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Discussion 
Dr. Davis C. Drinkwater, Jr. (Los Angeles, Calif.). This 
study is a timely one as the debate continues over which is 
the optimum cardioplegic composition and administration 
technique. Focusing as it does on retrograde cardioplegia 
alone, this report has great potential to further contribute 
to the literature. However, because of its design, the study 
is as significant for what it does not show as for what its 
findings and conclusions actually were. The goal of resus- 
citation cardioplegia fter a preoperative cardiac insult 
should be to allow the dual purpose of mechanical repair 
and metabolic correction during the same period of 
crossdamping. The rationale for integration of all modi- 
fications is that the exclusion of one component produces 
a reduced effectiveness, asindeed this study shows. 
Predictably, the first group, that of hypothermic cardio- 
plegia, has the worst overall result because this technique 
is incapable of repleting any metabolic deficits incurred 
with a 20-minute global ischemic time. 
The poor recovery in the second group with a combi- 
nation of warm induction and reperfusion with cold 
intermittent cardioplegia is somewhat perplexing and at 
variance with our experience and that of others. On closer 
inspection, one realizes that the protocol in which it was 
administered iffers importantly from previously de- 
scribed techniques using enhanced cardioplegia, in which 
it was established that the heart requires time to repair 
itself and replete its metabolic substrate debts. In this 
study, the maximum resuscitation period of normothermic 
induction and reperfusion is only 21/2 minutes each for a 
total protocol dose of 10 ml/kg per phase. This would 
achieve only partial and short-lasting recovery. Our pre- 
vious work shows that 20 minutes is required to replete 
the significant substrate debts in severely preinjured 
hearts such as those in cardiogenic shock with acute 
myocardial infarction. Would the authors consider ex- 
tending the warm induction and reperfusion phase to be 
more in line with previously established protocols using 
modified cardioplegia? 
Dr. Grossi. The purpose of using a shorter period of 
time was to make the overall dosages of amino acids the 
same. Also, at our institution, volume (with 20 ml/kg as 
the initial dose) is the primary criterion rather than time. 
We believe that the model is clinically relevant and the 
data speak for themselves. 
Dr. Drinkwater. Finally, probably the most significant 
finding of the study is to further question the benefit of 
warm continuous cardioplegia s the sole method of 
inducing and maintaining cardiac arrest during cross- 
damping. We have previously described, as has more 
recently the Boston University group, that retrograde 
cardioplegia lone has a variable and inhomogeneous 
distribution throughout both the left and right ventricles. 
Therefore, reliance only on retrograde cardioplegia may 
certainly cause inadequate distribution of solution to 
substantial portions of the heart and result in the poor 
outcome demonstrated in your group 3. Because of the 
variability of distribution in retrograde route and the need 
for substrate repletion in preinjured hearts, our routine 
clinical protocol is a 5-minute induction of warm cardio- 
plegia, with the solution given antegradely and retro- 
gradely to optimize its distribution. We then use cold 
intermittent cardioplegia to provide maintenance and 
optimum visualization during the repair, with a final 
period of warm cardioplegia for at least 5 minutes and up 
to 20 minutes in those hearts that have had a significant 
preoperative injury, such as those in cardiogenic shock. 
With this strategy, the mortality in that very troublesome 
group has been lowered from the 50% to 60% range down 
to 7% in our most recent series. 
In summary, I agree with the authors' findings, but I am 
at variance with their conclusions concerning amino acid- 
enhanced cardioplegia based on their protocol. I thank 
them for pointing out the inadequacy of a nonintegrated 
cardioplegic technique for myocardial protection and 
resuscitation. 
